Signal peptide of HIV-1 envelope modulates glycosylation impacting exposure of V1V2 and other epitopes
Open Access
- 28 December 2020
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Pathogens
- Vol. 16 (12), e1009185
- https://doi.org/10.1371/journal.ppat.1009185
Abstract
HIV-1 envelope (Env) is a trimer of gp120-gp41 heterodimers, synthesized from a precursor gp160 that contains an ER-targeting signal peptide (SP) at its amino-terminus. Each trimer is swathed by ~90 N-linked glycans, comprising complex-type and oligomannose-type glycans, which play an important role in determining virus sensitivity to neutralizing antibodies. We previously examined the effects of single point SP mutations on Env properties and functions. Here, we aimed to understand the impact of the SP diversity on glycosylation of virus-derived Env and virus neutralization by swapping SPs. Analyses of site-specific glycans revealed that SP swapping altered Env glycan content and occupancy on multiple N-linked glycosites, including conserved N156 and N160 glycans in the V1V2 region at the Env trimer apex and N88 at the trimer base. Virus neutralization was also affected, especially by antibodies against V1V2, V3, and gp41. Likewise, SP swaps affected the recognition of soluble and cell-associated Env by antibodies targeting distinct V1V2 configurations, V3 crown, and gp41 epitopes. These data highlight the contribution of SP sequence diversity in shaping the Env glycan content and its impact on the configuration and accessibility of V1V2 and other Env epitopes. HIV-1 Env glycoprotein is produced by a precursor gp160 that has a signal peptide at its N-terminus. The SP is highly diverse among the HIV-1 isolates. This study presents site-specific analyses of N-linked glycosylation on HIV-1 envelope glycoproteins from infectious viruses produced with different envelope signal peptides. We show that signal peptide swapping alters the envelope glycan shield, including the conserved N156 and N160 glycans located in the V1V2 region on the trimer apex, to impact Env recognition and virus neutralization by antibodies. The data offer crucial insights into the role of signal peptide in the interplay between HIV-1 and antibodies and its potential utility to control Env glycosylation in the development of Env-based HIV-1 vaccine.Keywords
Funding Information
- National Institutes of Health (AI140909)
- National Institutes of Health (AI124863)
- National Institutes of Health (AI124863)
- National Institutes of Health (AI145655)
- VA Merit Review Award (I01BX003860)
- VA Research Career Scientist Award (1IK6BX004607)
This publication has 121 references indexed in Scilit:
- Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escapeNature Medicine, 2012
- Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individualsVirology, 2012
- Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Nature, 2011
- Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 BindingScience, 2011
- HIV-1 Envelope Glycoprotein Biosynthesis, Trafficking, and IncorporationJournal of Molecular Biology, 2011
- Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1Science, 2010
- Glycosylation Patterns of HIV-1 gp120 Depend on the Type of Expressing Cells and Affect Antibody RecognitionOnline Journal of Public Health Informatics, 2010
- Protein annotation and modelling servers at University College LondonNucleic Acids Research, 2010
- Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine TargetScience, 2009
- Signal peptide fragments of preprolactin and HIV-1 p-gp160 interact with calmodulinThe EMBO Journal, 1997